AstraZeneca plc (LON:AZN) had its target price decreased by investment analysts at Jefferies Group from GBX 6,000 ($74.32) to GBX 5,600 ($69.37) in a research note issued on Friday. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s target price would indicate a potential upside of 27.14% from the company’s previous close.

A number of other equities analysts have also issued reports on the stock. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a research report on Friday. Shore Capital restated a “hold” rating on shares of AstraZeneca plc in a research report on Wednesday. Citigroup Inc. restated a “buy” rating on shares of AstraZeneca plc in a research report on Monday. Credit Suisse Group AG restated an “underperform” rating and set a GBX 4,000 ($49.55) target price on shares of AstraZeneca plc in a research report on Friday, November 4th. Finally, Morgan Stanley restated a “buy” rating and set a target price on shares of AstraZeneca plc in a research report on Wednesday, November 2nd. Five research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of GBX 4,951.42 ($61.33).

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Shares of AstraZeneca plc (LON:AZN) opened at 4404.50 on Friday. The company has a 50-day moving average of GBX 4,857.61 and a 200 day moving average of GBX 4,557.17. The stock’s market cap is GBX 55.72 billion. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.